On Dec. 23, 2022, BioNTech and Fosun Pharmaceutical announced that they had received the certificates of registration as pharmaceutical product in relation to the official registration of the monovalent COVID-19 vaccine (also known COMIRNATYﾮ Original) and the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (also known as COMIRNATYﾮ Original/Omicron BA.4/BA.5) by the Health Bureau of the Hong Kong Special Administrative Region of the Peopleﾒs Republic of China (ﾓHong Kongﾔ) which is equivalent to a Biologics License Application.